<?xml version='1.0' encoding='utf-8'?>
<document id="21568918"><sentence text="Interactions between clopidogrel and proton pump inhibitors: a review of evidence."><entity charOffset="21-32" id="DDI-PubMed.21568918.s1.e0" text="clopidogrel" /></sentence><sentence text="Clopidogrel is a thienopyridine, which inhibits the platelet P2Y adenosine diphosphate (ADP) receptor termed P2Y(12)"><entity charOffset="0-11" id="DDI-PubMed.21568918.s2.e0" text="Clopidogrel" /><entity charOffset="17-31" id="DDI-PubMed.21568918.s2.e1" text="thienopyridine" /><entity charOffset="65-86" id="DDI-PubMed.21568918.s2.e2" text="adenosine diphosphate" /><entity charOffset="88-91" id="DDI-PubMed.21568918.s2.e3" text="ADP" /><pair ddi="false" e1="DDI-PubMed.21568918.s2.e0" e2="DDI-PubMed.21568918.s2.e0" /><pair ddi="false" e1="DDI-PubMed.21568918.s2.e0" e2="DDI-PubMed.21568918.s2.e1" /><pair ddi="false" e1="DDI-PubMed.21568918.s2.e0" e2="DDI-PubMed.21568918.s2.e2" /><pair ddi="false" e1="DDI-PubMed.21568918.s2.e0" e2="DDI-PubMed.21568918.s2.e3" /><pair ddi="false" e1="DDI-PubMed.21568918.s2.e1" e2="DDI-PubMed.21568918.s2.e1" /><pair ddi="false" e1="DDI-PubMed.21568918.s2.e1" e2="DDI-PubMed.21568918.s2.e2" /><pair ddi="false" e1="DDI-PubMed.21568918.s2.e1" e2="DDI-PubMed.21568918.s2.e3" /><pair ddi="false" e1="DDI-PubMed.21568918.s2.e2" e2="DDI-PubMed.21568918.s2.e2" /><pair ddi="false" e1="DDI-PubMed.21568918.s2.e2" e2="DDI-PubMed.21568918.s2.e3" /></sentence><sentence text=" It is taken as a prodrug that requires biotransformation to an active metabolite by cytochrome P450 (CYP) isoenzymes" /><sentence text=" In addition, esterases shunt the majority of clopidogrel to an inactive pathway, whilst the remaining prodrug requires two separate CYP-dependent oxidative steps"><entity charOffset="46-57" id="DDI-PubMed.21568918.s4.e0" text="clopidogrel" /></sentence><sentence text=" PPIs might diminish the antiplatelet effects and the clinical effectiveness of clopidogrel possibly through inhibition of CYP2C19 and CYP3A4 isoenzymes"><entity charOffset="80-91" id="DDI-PubMed.21568918.s5.e0" text="clopidogrel" /></sentence><sentence text=" Treatment with clopidogrel and aspirin decreases recurrent cardiovascular events after an acute coronary syndrome"><entity charOffset="16-27" id="DDI-PubMed.21568918.s6.e0" text="clopidogrel" /><entity charOffset="32-39" id="DDI-PubMed.21568918.s6.e1" text="aspirin" /><pair ddi="false" e1="DDI-PubMed.21568918.s6.e0" e2="DDI-PubMed.21568918.s6.e0" /><pair ddi="false" e1="DDI-PubMed.21568918.s6.e0" e2="DDI-PubMed.21568918.s6.e1" /></sentence><sentence text=" However, an inherent increment of major bleeding is also associated with antiplatelet therapy, as well as dyspepsia with aspirin"><entity charOffset="122-129" id="DDI-PubMed.21568918.s7.e0" text="aspirin" /></sentence><sentence text=" Also, major bleeding has been associated with high risk for ischemic events and mortality" /><sentence text=" For this reason, a proton pump inhibitor (PPI) is often co-prescribed to reduce the risk of gastrointestinal tract bleeding, but its concomitant use might reduce the inhibitory effect of clopidogrel on platelet aggregation"><entity charOffset="188-199" id="DDI-PubMed.21568918.s9.e0" text="clopidogrel" /></sentence><sentence text=" Nevertheless, doubts exist about the possible interaction of concomitant PPI use that may reduce the inhibitory effect of clopidogrel on platelet aggregation"><entity charOffset="123-134" id="DDI-PubMed.21568918.s10.e0" text="clopidogrel" /></sentence><sentence text=" Indeed, there is some controversy with regard to the true risk of cardiovascular adverse events arising from a potential drug-drug interaction between clopidogrel and PPI"><entity charOffset="152-163" id="DDI-PubMed.21568918.s11.e0" text="clopidogrel" /></sentence><sentence text=" In this article, we will review the current status and controversies in relation to a possible interaction between clopidogrel and PPIs"><entity charOffset="116-127" id="DDI-PubMed.21568918.s12.e0" text="clopidogrel" /></sentence><sentence text="" /></document>